Sinotau Pharmaceutical Group, a Beijing-based nuclear medicine enterprise, has entered into a licensing agreement with UK molecular imaging company Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A. Through this deal, Sinotau will gain development, manufacturing, and commercialization rights to Blue Earth’s PSMA targeted PET imaging agent, Flotufolastat (18F).
Flotufolastat (18F): Technology and Approval
Flotufolastat (18F) is a cutting-edge positron emission tomography (PET) radiopharmaceutical that utilizes a novel RadioHybrid technology to target prostate-specific membrane antigen (PSMA) positive lesions. The agent received approval in the US in May 2023 for diagnosing newly diagnosed prostate cancer patients planning radical treatment and those with elevated prostate-specific antigen (PSA) levels and suspected biochemical recurrence.
Prostate Specific Membrane Antigen (PSMA) and Market Potential
PSMA is a type II transmembrane glycoprotein that is overexpressed in prostate cancer cells at all stages, with its expression levels correlating with tumor staging and grading. Currently, there is no PSMA-PET product available on the market in China, indicating a significant unmet need and potential market opportunity for Sinotau Pharmaceutical Group.-Fineline Info & Tech
